Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMVTKCX)

• Drug Name: POP-1 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Investigative	[1]

• Cross-matching ID: TTD Drug ID: DMVTKCX

Molecule-Related Drug Atlas

Drug(s) Targeting Cationic trypsinogen (PRSS1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Bortezomib	DMNO38U	Leukemia		Approved	[2]
MELAGATRAN	DM4W8RE	N. A.	N. A.	Phase 3	[3]
Ulinastatin	DMIQCFG	Premature labour	JB00	Phase 3	[4]
Alpha-1 antitrypsin	DM5EFXZ	Coagulation defect	3B10.0	Phase 2	[1]
Dermolastin	DM6WSU2	Atopic dermatitis	EA80	Discontinued in Phase 2	[5]
RWJ-56423	DM6BIHE	Asthma	CA23	Discontinued in Phase 1	[6]
Patamostat	DM6HBQJ	Hypotension	BA20-BA21	Terminated	[1]
BMY-44621	DM8R3N0	N. A.	N. A.	Terminated	[7]
Grassystatin a	DM1PWX2	Discovery agent	N.A.	Investigative	[8]
2-(2-Hydroxy-phenyl)-1H-indole-5-carboxamidine	DM3UMYD	Discovery agent	N.A.	Investigative	[9]

Drug(s) Targeting Alpha-glucosidase (GLA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cipaglucosidase alfa	DMAPDH2	Glycogen storage disease type II	5C51.3	Approved in EU	[10]
Cipaglucosidase alfa	DMAPDH2	Glycogen storage disease type II	5C51.3	Approved in EU	[11]
Deoxynojirimycin	DM2ATZB	Pompe disease	5C51.3	Phase 3	[12]
Anamorelin	DM6HXTS	Carbohydrate metabolism disorder	5C51.Z	Phase 3	[13]
Maltose	DMH0ROP	N. A.	N. A.	Phase 1/2	[14]
AAV2/8-LSPhGAA	DMIX5HF	Pompe disease	5C51.3	Phase 1	[15]
Nicotinamide-Adenine-Dinucleotide	DM9LRKB	N. A.	N. A.	Investigative	[16]
Beta-D-Glucose	DM5IHYP	Discovery agent	N.A.	Investigative	[16]
Double Oxidized Cysteine	DM6TU84	Discovery agent	N.A.	Investigative	[16]
JBP-1	DM0KMPN	Solid tumour/cancer	2A00-2F9Z	Investigative	[1]

Drug(s) Targeting Chymotrypsin (CTR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Pancrecarb	DMOML9Q	Pancreatic malfunction	DC30-DC3Z	NDA filed	[1]
Liprotamase	DMNF4UH	Cystic fibrosis	CA25	Phase 3	[17]
CM-AT	DMLMN2F	Attention deficit hyperactivity disorder	6A05.Z	Phase 3	[18]
JBP-1	DM0KMPN	Solid tumour/cancer	2A00-2F9Z	Investigative	[1]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Alpha-glucosidase (GLA)	TTHCF4J	LYAG_HUMAN; GANAB_HUMAN; GANC_HUMAN	Modulator	[1]
Cationic trypsinogen (PRSS1)	TT2WR1T	TRY1_HUMAN	Modulator	[1]
Chymotrypsin (CTR)	TT7MRGU	NOUNIPROTAC	Modulator	[1]

References

• [1] US patent application no. 2012,0251,516, PHARMACEUTICAL COMPOSITION FOR TREATING CANCER COMPRISING TRYPSINOGEN AND/OR CHYMOTRYPSINOGEN AND AN ACTIVE AGENT SELECTED FROM A SELENIUM COMPOUND, A VANILLOID COMPOUND AND A CYTOPLASMIC GLYCOLYSIS REDUCTION AGENT.
• [2] Characterization of a class of peptide boronates with neutral P1 side chains as highly selective inhibitors of thrombin. J Med Chem. 1995 Apr 28;38(9):1511-22.
• [3] Orally active thrombin inhibitors. Part 1: optimization of the P1-moiety. Bioorg Med Chem Lett. 2006 May 15;16(10):2641-7.
• [4] Intravenous administration of ulinastatin (human urinary trypsin inhibitor) in severe sepsis: a multicenter randomized controlled study. Intensive Care Med. 2014 Jun;40(6):830-8.
• [5] Arriva-ProMetic recombinant alpha 1-antitrypsin (rAAT) moves into the clinic for dermatology applications. ProMetic Life Sciences. 2009.
• [6] Inhibitors of serine proteases as potential therapeutic agents: the road from thrombin to tryptase to cathepsin G. J Med Chem. 2004 Feb 12;47(4):769-87.
• [7] Design and synthesis of conformationally constrained arginal thrombin inhibitors, Bioorg. Med. Chem. Lett. 7(17):2205-2210 (1997).
• [8] Grassystatins A-C from marine cyanobacteria, potent cathepsin E inhibitors that reduce antigen presentation. J Med Chem. 2009 Sep 24;52(18):5732-47.
• [9] Development of serine protease inhibitors displaying a multicentered short (<2.3 A) hydrogen bond binding mode: inhibitors of urokinase-type plasmi... J Med Chem. 2001 Aug 16;44(17):2753-71.
• [10] Cipaglucosidase Alfa: First Approval. Drugs. 2023 Jun;83(8):739-745.
• [11] FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 761204
• [12] Nitrogen-in-the-ring pyranoses and furanoses: structural basis of inhibition of mammalian glycosidases. J Med Chem. 1994 Oct 28;37(22):3701-6.
• [13] Absorption, elimination, and metabolism of CS-1036, a novel -amylase inhibitor in rats and monkeys, and the relationship between gastrointestinal distribution and suppression of glucose absorption.Drug Metab Dispos.2013 Apr;41(4):878-87.
• [14] DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41.
• [15] ClinicalTrials.gov (NCT03533673) AAV2/8-LSPhGAA in Late-Onset Pompe Disease. U.S. National Institutes of Health.
• [16] How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
• [17] Clinical pipeline report, company report or official report of Anthera Pharmaceuticals.
• [18] Drugmakers dance with autism. Nat Biotechnol. 2010 Aug;28(8):772-4.